#1INNOVATION WITH INTEGRITY Bruker Corporation (Nasdaq: BRKR) Emerging Leader of the Post-Genomic Era Frank H. Laukien Bruker Chairman, President & CEO San Francisco, CA - January 8, 2024 2024 JP Morgan Healthcare Conference BRUKER#2BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our preliminary fourth quarter and fiscal year ended December 31, 2022 operational and financial performance, including our revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; ROIC; EBITDA; management's expectations for future financial and operational performance, expected growth, and business outlook; statements regarding our business focus, expected market growth and market size; and product performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions, the impact of any supply chain disruptions, continued volatility in the capital markets, the impact of Project Accelerate, the performance of breakout opportunities, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates and their impact, our ability to successfully implement our restructuring initiatives and other cost reduction initiatives, changing technologies, product development and market demand and acceptance of our products, the success of our R&D investment initiatives, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborative partners, key suppliers and contract manufacturers, capital expenditures, debt levels, payment of dividends, government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2022, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law. 2023 Bruker BRUKER Innovation with Integrity | January 8, 2024 I 2#3BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY ■ Dual strategy of Project Accelerate 2.0 and Operational Excellence works Project Accelerate 2.0 Initiatives ▪ Pull up growth and EPS Re-positioning Bruker for high-growth, high- Assays, Software margin opportunities & Aftermarket Building unique, leading platforms for novel applications, life-science solutions Enabling research in cell and disease biology: large TAMS, strong secular growth ▪ Project Accelerate 2.0 at ~56% of revenue, with DD revenue CAGR → Major benefits from Al and Clean-Tech → Leadership in the Post-Genomic Era © 2023 Bruker Next-gen Nano & Semi Tools Unbiased Proteomics & Multiomics BRUKER Biopharma & Applied Microbiology & Molecular Dx Spatial Biology, Single-Cell Omics, Cellular Analysis Operational Excellence ▪ Push up market share, gross margin ▪ Bruker Management Process drives execution and predictability ■ BRUKER ■ Operational, commercial and product R&D excellence Disciplined execution: significant R&D investments, while delivering organic margin expansion and non- GAAP EPS growth - all at high ROIC Prudent capital allocation with conservative margin of safety Innovation with Integrity | January 8, 2024 I 3#4BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Key Strategy Pillar: Operational Excellence & Productivity Investments ▪ Excellence in Operations, Commercial and Product R&D Driving growth, expanding gross and operating margins organically Proven progress and foundation for further investments and sustainable growth Strong focus on cash-flow generation post-supply chain crisis ■ ■ Operational Efficiency & Productivity New Bremen Mass Spec Facility with 2x capacity © 2023 Bruker all Commercial Excellence & Risk Management Remote Service, Training and Installations Product R&D Excellence Σ=3415 BRUKER Portfolio Management, NPV/IRR-driven R&D Innovation with Integrity | January 8, 2024 | 4#5BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Major R&D Investments Advancing Purposeful Innovation Industry-leading Strategic R&D Investments: ▪ Drives product innovation, #1 or #2 positions, growth, margins and EPS Fast growth in proteomics, spatial biology, IVD, biopharma, semicon for Al Strategy to drive Leadership in the Post-Genomic Era I timsTOF® 4D-Proteomics Beacon® Single-Cell Biology IsoSpark Single-Cell Omics Canopy Spatial Proteomics Acuity 3D Spatial Genomics Cancer & Neuroscience Research Tools 4D-Epiproteomics 4D-Lipidomics 4D-Metabolomics 4D-Glycobiology 2023 Bruker MALDI Biotyper MBT Sepsityper IVD Molecular Diagnostics: LiquidArray PCR Panels GHz NMR Functional Structural Biology Translational Phenomics by NMR and MS R&D AS % OF REVENUE 10% 10% 9% High-performance Instruments, Solution Leadership, Deep Biology and Disease Expertise 2021 Automation NMR & MS: Unique for Biologics Biopharma PAT Biopharma Software & BRUKER HI HI 2023-E 2026-E Leading Nano Tools: Semicon Tools for Al CleanTech Tools Superconductors for MRI, Fusion, Wind Innovation with Integrity | January 8, 2024 15#6BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Unique capabilities: NMR and EPR as Cleantech Analytical Techniques Example: Battery Value Chain - Research, Production & Recycling Mining Electrode Production Battery Cell Conditioning Materials Mixing }{ L Coating }{ Formation Cell Aging Drying Battery Recycling Packing 1 Solvent Recovery Calendering Integration M.GI 3315 End-of-Life Shredding Slitting s H Electrolyte Recovery Upcycling Re-Lithiation Innovation with Integrity BRUKER Recycling January 8, 2024#7BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Unique capabilities: MALDI Biotyper® with Novel Applications Installed Base Grows Steadily, >50% Recurring Revenues ▪ Leader in microbial ID by proteomic fingerprinting in clinical and applied markets ▪ Faster and more cost-effective ID of bacteria and fungi Near-universal microbial species coverage from cultures ■ MALDI Biotyper" sirius Technology Leadership ▪ MALDI-TOF technology leadership ▪ MALDI Biotyper® sirius enables novel lipidomics assays - Ruo Sepsityper accelerates US growth ▪ MBT Compass: 600 samples/hr 2023 Bruker ■ MALDI Biotyper sirius CARE 02 MBT Sepsityper IVD Kit BRUKER Market Expansion & Installed Base Growth >6,000 MALDI Biotyper® customer systems ▪ >100 million IDs per year ▪ >50% of revenues recurring, >10% CAGR of assay, consumables and service aftermarket I Innovation with Integrity | January 8, 2024 I 7#8BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Core innovation: Advancing Materials Science & Clean-Tech Research Bruker materials science research and testing solutions drive process and product improvements Applications in energy storage, drug delivery and additive manufacturing 2023 Bruker D6 PHASER & D6 PHASERTM X-Ray Diffraction (XRD) System Innovative benchtop design with high X-ray power and versatile X-ray optics > Advanced XRD methods for applied markets, like clean energy DIFFRAC.SUITE software for automated methods or customized configurations Hysitron TI 990 Tribolndenter® Nanomechanical Test System Polymer research, alloy development, and semiconductor device R&D > Increased flexibility, higher throughput > Top-view navigation streamlines setup in TriboScan 12 software for remote operation Innovation with Integrity | BRUKER B BRUKER January 8, 2024 HYSITRON TI 990 I 8#9BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Unique capabilities: Semicondutor Metrology for Artificial Intelligence Enables R&D and QC for novel CPU & GPU Chips, HBM Chips, Systems on Chip (Soc), FPGAs XRD Enables Next-Gen Chip Manufacturing Sirius-XRD 10x faster throughput. Won first multi-tool orders for pilot production QC at 3 leading semiconductor manufacturers BRUKER Sirius-XRD 2023 Bruker Sirius ● 3 nm logic moved to Gate-All- Around (GAA) design with multiple SiGe epi-layers We enable Ge concentration monitoring for etch control critical to device performance SiGe 45% SiGe 35% SiGe 25% SiGe 15% Advanced QC for 3D Chips Packaging ContourSP-S 35% throughput improvement InSight-WLI High resolution wafer-level packaging metrology Conta Ge concentration in GAA stack ContourSP-S already ~$75M of FY23 Bruker revenue driven by Al trends ● Chip packaging has moved to 3D We enable micron-scale interconnect process control Insight-WLI BRUKER Innovation with Integrity | January 8, 2024 I 9#10BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY New Scientific Software Initiative: Bringing Instruments and Data into Holistic Lab Workflows New BioSpin Integrated Data Solutions (IDS) Division Arxspan Mestrelab Research Analytical data processing, data analysis and lab automation 2023 Bruker Scientific Data Management (Electronic Laboratory Notebook and other modules) 5●●●●●●●●●●● Industrial Technologies Solution for real time process control and industrial automation ZONTAL. Scientific Data Management, Workflow Execution, and Insights BRUKER IDS Scientific Software ➤ Vendor independent integrated data solutions Individual capabilities, leveraging synergies for integrated solutions ► Agile development, open interfaces and collaborations ➤ Focus on user experience and customer value Innovation with Integrity | January 8, 2024 I 10#11■ ■ BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY New Opportunities: BEST Cleantech Technologies ■ Growing Cleantech markets for differentiated BEST cleantech tools BEST Cleantech technologies for future fusion power and next-gen offshore wind turbine prototypes Fusion Research & Pilot Fusion Power Plants Magnetic confinement fusion promises clean, renewable and safe baseload energy to replace fossil fuel and fission reactors Bruker and Rl over the years have received >$200M of multi-year orders for key technologies for major fusion projects Bruker is co-founder of Gauss Fusion Initiative (www.gauss-fusion.com) © 2023 Bruker ■ ■ research instruments 34 34 3 4000 Inner Vertical Targets (above) by RI Research Instruments to withstand extreme plasma heat loads at ITER New RI subcontract for plasma heating technologies for ITER Novel, high-current RRP® superconductors (left) by BEST for fusion pilot project in Asia (recently received 2nd tranche order) BRUKER Emerging Opportunity: Superconductors for Wind Turbines Superconductors enable novel efficient, smaller, and lighter- weight high-power wind turbines for offshore wind energy Superconductors could replace rare earth materials in future high-power wind turbines (>20 MW) Bruker has delivered superconductors for an off-shore wind turbine prototype, funded by US DOE Innovation with Integrity | January 8, 2024 1 11#12BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY Project Accelerate & Operational Excellence: Disciplined entrepreneurialism at work Bruker Management Process and culture of Disciplined Entrepreneurialism drive profitable growth Successful transformation into a fast growth company: On track for three consecutive years of >10% organic revenue growth in 2021-2023 Goal to grow revenue organically 200-300 bps above market in 2024-2026 Goal of >10% non-GAAP EPS CAGR in 2024-2026, with continued high RolC ● ● ● BRUKER Investing in large secular opportunities Proteomics/Multiomics and Spatial/Single-Cell Biology Bruker is an Emerging Leader of the Post-Genomic Era in the life-science tools (LST/Dx) sector 2023 Bruker Innovation with Integrity | January 8, 2024 I 12#13Q4 2023 UPDATE First 1.2 GHz NMR in U.S. at The Ohio State University Milestone in advancing US life science and materials research infrastructure, with leadership and funding by National Science Foundation Study of advanced materials (e.g., for batteries) ▪ Research structure and dynamics of biological macromolecules ▪ Advance understanding of mechanisms of diseases, such as cancer, cardiovascular disease, viral infections, Alzheimer's disease ▪ OSU 1.2 GHz NMR acceptance in Q4-23 ▪ 1.1 GHz solid-state NMR accepted in Q4-23 at U. Wisconsin-Madison ▪ Over 20 GHz-class NMRs installed worldwide by end of 2023 ■ ■ 2023 Bruker WHOREN BRUKER 1.2 GHz Avance® NMR system at The Ohio State University "The 1.2 GHz NMR instrument gives us the capability to explore the structure and dynamics of biological molecules at an unprecedented level of detail. This breakthrough will enable significant advances in our understanding of how these molecules function, ultimately leading to the development of new treatments for diseases." Dr. Rafael Brueschweiler, professor of chemistry and biochemistry at The Ohio State University, Pl of National Gateway Ultrahigh Field NMR Center Innovation with Integrity | January 8, 2024 I 13#14Q4 2023 UPDATE Expanding Portfolio via Acquisitions Tornado Spectral Systems for Biopharma PAT gutornado HyperFlux™ PRO Plus Raman system Process Guardian Raman 2023 Bruker Stornado ** spectral systems 58 0 a lomado Process Guardian" Raman spectrometer TM Acquired in early January 2024 (~$5M p.a. revenue) Manufacturer of Raman analysis systems, founded 2013 in Canada Patented HTVS™ technology enables difficult Raman measurements More accurate chemical ID and Quant in mixtures, or low concentrations High-performance Raman probes for different process environments Nion LLC for Leading High Performance Scanning Transmission Electron Microscopes ! nion Nion HERMES 100 Nion HERMES™ 100 BRUKER Twisted bilayer graphene Company acquired in early Jan. 2024 (>$10M revenue forecast for 2024) Develops and manufactures innovative high-end scanning transmission electron microscopes (STEM) Innovation with Integrity | Unique products for the most demanding research applications in materials science electron microscopy and new applications in electron diffraction crystallograph A company with a series of "first innovations" in STEM January 8, 2024 I 14#15Q4 2023 UPDATE YTD Q3 2023: Robust Organic Revenue Growth & EPS Growth Healthy Preliminary Q4-23 Revenue Growth; Solid FY24 Outlook ✰ Revenue increased ~$288M, up +15.8% Organic revenue growth +13.9% BSI +14.0% ■ YTD Q3-23A Financials (year-over-year) ■ Acquisitions +2.0%, FX -0.1% Non-GAAP EPS $1.50, up +12.8% BEST +12.8% BSI Geographic Revenue Mix YTD 3Q 2023 32% 2023 Bruker 33% ROW ~4% 31% BRUKER Q4-23E Preliminary Estimates; FY24E Outlook Q4 2023 Preliminary Estimates: ▪ Q4-23 revenue >$830M, with >12% organic growth ▪ Q4-23 reported revenue >$35M above consensus ▪ Q4-23 BSI bookings solid, including strong demand for NMR ▪ FY23 revenue >$2.94B, with >13% organic growth ▪ FY23 double-digit organic revenue & BSI bookings growth in China FY 2024 Preliminary Outlook: ▪ FY24 guidance in early February on Q4-23 earnings call ▪ For FY24, we expect solid, above-market organic revenue growth and non-GAAP EPS growth Innovation with Integrity | January 8, 2024 1 15#16BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA Leading timsTOF® Platform for Proteomics and other key Multiomics fields Leading Solutions for Single-Cell, Spatial, Structural, Quantitative & Interaction Biology Genomics: DNA instructions, monogenic diseases, precision oncology, viral diagnostics Genomics, Epigenetics & Transcriptomics PCR and NGS tools 2023 Bruker MS, NMR, Microscopy for Proteomics and Multiomics Key Systems Biology and Disease Insights Proteomics, Epiproteomics/PTMs, Glycomics, Lipidomics, Metabolomics; Spatial Biology and Single-Cell Biology; Tissue, Cell and Disease Biology; Quantitative and Interaction Biology; Chemical Biology; Drug Discovery; %% Expression Levels Proteins, PTMs, Lipids, Glycans & Metabolites have key functions in cell and disease biology (e.g., >1M protein variants vs 21k human genes) on off Post-Translational Modifications BRUKER Protein Structure / Conformation Innovation with Integrity | Protein - Protein Interactions January 8, 2024 I 16#17BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA Very Large TAMs and High Secular Growth in Proteomics & Spatial Biology Essential Proteins and metabolites perform most functions in the body 2023 Bruker Single Cell Tissue Plasma Complex ~21k genes, yet millions of proteoforms, infinite PTM combinations Main case of brands Clyphes Segolande HINA 4D-Lipidomics 4D-Metabolomics 4D-Multiomics 4D-Glycomics Virtuous Cycle Ever more sensitive instruments and powerful software unlocking deeper biological insights, for precise diagnosis and better therapeutics 4D-Proteomics 4D-Epiproteomics BRUKER Human colon cancer FFPE sample imaged with Canopy's CellScape Spatial Immune Profiling Kit Innovation with Integrity | January 8, 2024 I 17#18● BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA timsTOF Platform Advancing 4D-Proteomics → Unmatched Robustness (~60 SPD-200 SPD) Unparalleled Duty Cycle (PASEF, diaPASEF, prmPASEF, capsPASEF) * High-Throughput Omics (5min, 20min methods) * Identify more PTMs (Mobility Offset Mass Aligned - MOMA) Higher Confidence ID with CCS values (TIMScore, CCS-Predict, AI/DL) → Single Cell Proteomics (Deep Visual, MALDI-Guided, LCM spatial) timsTOF Platform: Unbiased Discovery and Quant at depth and scale with 1% FDR (without antigen cross-reactivity) Update end of FY 2023: Installed base >800 units timsTOF Ultra introduced 2022 Bruker timsTOF Pro 2 Ultimate Workhorse 16,000 14,000 12,000- 10,000 8000 6000- 4000- 2000 0 timsTOF HT Ultimate Workhorse Extended Range diaPASEF, diaNN 1.8 SwissProt predicted library 7 ng K562 digest on column 1200 1400 TOFU 2000 Launched June 2023 Precursors Identified stripped sq Proteins Identified timsTOF Ultra Ultimate Sensitivity Innovation with Integrity | BRUKER timsTOF HT: More than 100,000 unique peptides identified with 60-minute nLC gradient using dia-PASEF method timsTOF flex Ultimate Flexibility January 8, 2024 I 18#19BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA Functional Structural Biology: Understanding Disease with GHz NMR NMR in Pharmacology NMR in (Un-)structural Biology Intrinsically Disordered Proteins (IDPs) GPCRs as Key Drug Targets Liquid-Liquid Phase Separation which RNA to choose? IDPs implicated in protein aggregation in Alzheimer's, Parkinson's, Diabetes-ll and Creutzfeldt-Jakob diseases NMR in RNA-Protein Complexes Accelerates RNA Drug Discovery ▪ RNA structure & RNA-target interactions ▪ RNA pathways and RNA-binding Antagonist Spontaneous transition Inactive Antagonist selects inactive receptor conformation Unfolded Cycling Agonist www Active Agonist selects active receptor conformation Radio frequency heating Folded BRUKER ▪ NMR key to G-Protein Coupled Receptors (GPCR) conformational studies NMR in 4D-Biology Biological Processes in Space and Time Innovation with Integrity January 8, 2024#20BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA Canopy CellScape® System - Truly Quantitative Spatial Biology for Cancer Research, Immuno-Oncology, Neuroscience Differentiating Truth Matters Differentiated Quantitation Robust, Protocol for Path to Results Truly Getting Markers to High-Plex Why You Should Really Care See entire spatial neighborhood/phenotype Get productive without lengthy assay development No complex custom marker development / no sample degradation by protocol © 2023 Bruker For Research Use Only. Not for use in clinical diagnostic procedures. CellScape® Platform Differentiated quantitative performance in spatial proteomics CellScoper (canopu Best In Class Optical Resolution 182 nm/pixel canopy BRUKER High Dynamic Range (HDR) & Quantitative Al low moderate high 8-log dynamic range Innovation with Integrity | January 8, 2024 I 20#21BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA Bruker Cellular Analysis: Beacon® Accelerates Discovery of Antibodies and of Cell-Based Cancer Therapies Leveraging the unique Beacon (former Berkeley Lights) platform: Development of T cell receptor T cell (TCR-T) and chimeric antigen receptor T cell (CAR-T) therapies against novel cancer antigens High-throughput cell-based CAR-T cell workflow tests capacity of CAR constructs ▪ Integration of multimodal data to predict CAR-T cell function and clinical efficacy ▪ Streamlining translation of cell-based therapies to the clinic ■ ■ © 2023 Bruker FINOMS BRUKER Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy Dr. Zamora and publication in Frontiers of Immunology in Dec. 2023 Innovation with Integrity | "... single cell platform, such as the Beacon, can link phenotypic, functional, and transcriptomic profiles of neoantigen-reactive T cells to expedite translation of cell-based therapies to the clinic" - Anthony Zamora, Assistant Professor, Medicine (Hematology and Oncology) and Microbiology and Immunology, Medical College of Wisconsin January 8, 2024 1 21#22BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA Bruker Cellular Analysis: Beacon® Enables Potential Breakthroughs in Vaccine Development Dr. Facundo Batista, MIT professor, Ragon Institute: Focus on B cells and antibody responses in new vaccination strategies for intractable pathogens, such as malaria, influenza, and HIV ■ ■ I Acquired Beacon in Dec. 2023 to identify mechanisms connecting B cells with T cells and NK cells in immune response to viral infections Accelerate breakthroughs in vaccine development, other therapeutics Beacon® Optofluidic System: The True Single-Cell Functional Multi-omic Platform Analyze up to 20,000 live individual cells and cell-cell interactions simultaneously Serial, multi-parameter functional assays of single cells and cell-cell interactions Serial Ag Binding Surface or secreted phenotype © 2023 Bruker Beacon 6 11111111111 Dr. Facundo Batista Associate Director and Scientific Director; Phillip and Susan Ragon Professor, MIT "...HIV and malaria are two of the deadliest pathogens with >1.2 million deaths annually combined. The Beacon holds promise in fighting infectious diseases and deliver help to populations who need it most." BRUKER Link functions with genotype Selectively export live cells for analysis: > Proteome & Transcriptome > TCR / BCR/CAR Sequence ENSGD0000164687-FABPS Innovation with Integrity | EKSGODOC0115523-GNLY January 8, 2024 1 22#23BRUKER AN EMERGING LEADER OF THE POST-GENOMIC ERA Enabling Post-Genomic Era Research, Drug Discovery and Diagnostics 2022 Bruker >25% Revenue Mix 2023 Bruker Post-Genomic Life-Science Tools and Diagnostics >$650M revenue p.a. Virtuous Cycle, enabling technology: high-performance instruments, automation, consumables and software unlock post-genomic biology for research, better Dx and better drug discovery & development MALDI Biotyper" sirius MALDI Biotyper Microbiology Crystallography Structural Biology tims TOFlex tims TOFⓇ 4D-Proteomics 4D-Multiomics CelScope BRUKER GHz-NMR Functional Structural Biology Ascend 1.2GHz Innovation with Integrity | canopy CellScape Spatial Biology January 8, 2024 I 23#24■ ■ ■ BRUKER AN EMERGING LEADER OF THE POST-GENOMIC ERA ■ Dual strategy of Project Accelerate 2.0 and Operational Excellence works Project Accelerate 2.0 Initiatives Pull up growth and EPS Re-positioning Bruker for high-growth, high-margin opportunities Building unique, leading platforms for novel applications, life-science solutions Enabling research in cell and disease biology: large TAMS, strong secular growth Project Accelerate 2.0 at ~56% of revenue, with DD revenue CAGR → Major benefits from Al and Clean-Tech Assays, Software & Aftermarket 2023 Bruker Next-gen Nano & Semi Tools Unbiased Proteomics & Multiomics BRUKER Biopharma & Applied Microbiology & Molecular Dx Spatial Biology, Single-Cell Omics, Cellular Analysis Operational Excellence ▪ Push up market share, gross margin ▪ Bruker Management Process drives execution and predictability ■ ■ BRUKER Operational, commercial and product R&D excellence Disciplined execution: significant investments and organic margin expansion, non-GAAP EPS growth, all at high ROIC → Emerging Leadership of the Post-Genomic Era Prudent capital allocation with conservative margin of safety Innovation with Integrity | January 8, 2024 I 24#25Innovation with Integrity BRUKER c